The BEACON Study (BrEAst Cancer Outcomes with NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician�s Choice (TPC) in Patients with Locally Recurrent or Metastatic Breast Cancer Previously Treated with an
Read time: 1 mins
Last updated:29th Mar 2012
To compare the Overall Survival (OS) of patients who receive NKTR-102 given once every 21 days to patients who receive TPC selected from the following list of seven single-agent intravenous therapies: eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel or nab-paclitaxel.
|Study start date||2012-03-29|